Cervical Cancer Biomarkers in Non-Cervical Samples: Emerging Tools for Diagnosis and Prognosis

Area of Science:

• Gynecologic Oncology
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Cervical cancer (CC) remains a leading cause of cancer death globally, primarily caused by high-risk human papillomavirus (HPV) genotypes.
• Current screening methods face challenges due to patient discomfort and low uptake, contributing to persistent high incidence and mortality rates.
• Effective early detection and monitoring are crucial for improving CC outcomes.

Purpose of the Study:

• To review current diagnostic methods for cervical cancer.
• To highlight recent advances in identifying biomarkers for CC in non-cervical samples.
• To discuss the potential clinical utility and future perspectives of these novel biomarkers.

Main Methods:

• Literature review of diagnostic methods for cervical cancer.
• Analysis of recent research on biomarkers in non-cervical samples (blood, urine, vaginal fluids).
• Evaluation of biomarker sensitivity, specificity, and potential for diagnosis, prognosis, and monitoring.

Main Results:

• Numerous biomarkers have been identified in non-cervical samples with high efficacy for CC detection.
• These biomarkers show potential for early disease identification and patient monitoring.
• Non-cervical sample analysis may reduce patient discomfort associated with traditional cervical sampling.

Conclusions:

• Biomarkers in non-cervical samples offer a promising alternative for cervical cancer screening and management.
• Wider adoption of these tests could significantly reduce CC incidence and mortality rates.
• Further research and clinical validation are needed to integrate these biomarkers into routine practice.